Weight-loss medications containing GLP-1 analogues are increasingly reported to have an unexpected but profound side effect: dramatically reducing patients' desire and physical capacity to consume alcohol. While drugs like Wegovy, Ozempic, and Mounjaro are primarily prescribed to suppress appetite and aid in shedding weight, a growing number of users are discovering that their cravings for alcohol have diminished or vanished entirely.
This unexpected shift is reshaping the social lives and health profiles of patients, sparking significant interest among clinical researchers investigating the link between these medications and addiction.
For 46-year-old Lisa Rees from South Wales, who began her weight-loss medication journey in April, the reduction in her drinking habits has been the "best benefit" of the treatment. Before starting the drug, Rees regularly drank between six and eight bottles of wine a week with her friends, sometimes worrying about the long-term impacts on her health. The National Health Service (NHS) warns that regularly drinking over 14 units a week—equivalent to about six medium glasses of wine or six pints—can lead to severe health issues, including liver damage, high blood pressure, and an elevated risk of cancer.
Since starting the medication, Rees has more than halved her alcohol intake. She previously used to drink two bottles of wine on a single night out, but now finds that after just a couple of glasses, she physically cannot drink another drop. During a recent nine-hour day festival, she consumed only three glasses of wine; in the past, she would have drank two full bottles of wine and a couple of vodka mixers. This change has allowed her to remain socially active without the pressure of heavy drinking.
When Rees previously tried to stop drinking for a few weeks in the late 2010s, she noticed friends stopped inviting her to social gatherings, which eventually led her back to drinking. With the medication, she still feels included because she can drink a small amount, even though she simply cannot stomach any more after a couple of glasses.
Another patient, 45-year-old Warren Thomas from Colchester, experienced an even more rapid shift after starting Mounjaro in mid-June. Thomas, who previously enjoyed a casual beer with his family after work and participated in one or two heavy drinking sessions each month with friends, was warned by friends already on the medication that it could alter his drinking habits. He noticed the effect within 24 hours of his first dose.
Thomas describes having zero appetite for alcohol now. When attending a friend's birthday last month, he felt light-headed and slightly giddy after consuming just two beers, leading him to conclude that his tolerance level to drinking is now zero. The change has put him off going out for drinking sessions entirely, a development he describes as very refreshing.
The biological mechanism behind these experiences lies in how these drugs interact with the body and brain. Medications like Wegovy, Ozempic, and Mounjaro contain active ingredients such as semaglutide or tirzepatide, which mimic GLP-1, a naturally occurring hormone. While GLP-1 is known for suppressing appetite and keeping people feeling full, early scientific research indicates it also influences the brain's reward pathways.
Dr. Christian Hendershot of the University of South Carolina explains that by affecting these reward responses, the drugs can decrease cravings for addictive substances, including alcohol and nicotine.
Dr. Hendershot published a small-scale study in 2025 showing that participants diagnosed with alcohol use disorder—defined by the NHS as drinking in a harmful way—experienced fewer cravings for alcohol while taking Ozempic. Additionally, a study from the University of Colorado Anschutz published last week indicated that oral GLP-1 medications led to a reduction in heavy drinking days for individuals with mild to moderate alcohol use disorder.
While observational data shows that the general population drinks less overall while taking these weight-loss drugs, clinical trials have primarily targeted individuals with diagnosed alcohol use disorder rather than casual drinkers.
Despite these clinical findings, medical guidance remains cautious. Professor Russell Hearn, a GP and professor of medicine at King's College London, notes that there is currently no formal advice in the British National Formulary—the dispensing guide used by UK doctors and pharmacists—regarding whether patients on weight-loss drugs should abstain from alcohol. However, Hearn advises his own patients to limit their drinking, pointing out that alcohol contains a high number of calories, meaning that reducing intake will naturally assist with weight-loss goals alongside dietary changes while on a GLP-1 medication.
For some younger users, however, the sudden physical aversion to alcohol has introduced difficult social hurdles. Faye Goodwin, a 20-year-old recent graduate who began taking Mounjaro at age 18, shared her experience, explaining that the medication has hampered her social life. Whenever she attempts to drink alcohol, she quickly experiences severe nausea, vomiting, or painful acid reflux. Having been on the medication throughout her late teens, Goodwin has rarely experienced drinking alcohol without its side effects, though she noted that during a one-month break from the injections, she was able to drink without any nausea.
Because alcohol plays a major role in socializing for people her age, Goodwin has found the side effects isolating, particularly during her time at university in Cambridge, where many social events revolved around drinking. She has struggled to enjoy events while sitting sober while others drink, often unable to finish even a single glass of wine due to overwhelming nausea.
To cope, she sometimes delays her weekly injection by a day if she plans to go out, as she finds the medication's impact on alcohol tolerance is strongest in the 48 hours following a dose. She has also declined social invitations outright if she has already taken her injection that day.
As experiences vary, researchers are pushing for more comprehensive data. Dr. Joseph Schacht, who led the study on weight-loss pills and alcohol, emphasizes that larger, longer-term studies with more participants are required before regulatory bodies can approve GLP-1 drugs specifically for treating alcohol use disorder. Meanwhile, Dr. Hendershot notes that data is accumulating very quickly, and some medical facilities in the United States are already prescribing these medications off-label to treat alcohol use disorder.
However, significant questions remain regarding the broader application of these drugs for addiction. Dr. Darren Quelch, an addiction researcher at the University of South Wales, has engaged with individuals receiving alcohol addiction support to discuss their thoughts on using weight-loss drugs as a treatment. Quelch highlights several unresolved issues, including whether it is safe for individuals who do not have obesity or diabetes to use these medications for addiction, as well as concerns over affordability.
Furthermore, the drugs carry potential side effects, including rare but serious conditions such as pancreatitis. Despite these hurdles, researchers continue to explore whether GLP-1 medications could eventually serve as effective treatments for other substance addictions, including nicotine and opioids.
"I still feel involved in things because I'm still drinking but drinking a lot less," Lisa says.
